After [losing out to Pfizer]( ...

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Danish drugmaker Novo Nordisk has partnered Emcure Pharmaceuticals to commercialise Poviztra, a 2.4 milligram (mg) ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...